Nymox pharmaceutical corp (NYMX)
Income statement / Quarterly
Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17
Revenues
Sales of goods

40

88

152

106

31

9

78

Total revenues

40

88

152

106

31

9

78

Operating expenses
Research and development

1,654

1,549

1,957

2,460

2,153

1,585

1,676

General and administrative

1,171

935

-

-

2,412

987

-

Marketing

0

0

794

4,302

0

7

1,119

Cost of sales

25

24

59

44

33

27

45

Total expenses

2,850

2,508

2,810

3,415

4,598

2,606

2,840

Loss from operations

-2,810

-2,420

-2,658

-3,309

-4,567

-2,597

-2,762

Net finance income (costs)

-19

-1

6

-369

15

108

52

Loss attributable to the equity holders

-2,791

-2,419

-2,664

-3,478

-4,582

-2,705

-2,664

Income tax provision (recovery)

-

-

0

-

-

-

0

Net loss

-

-

-2,664

-

-

-

-2,814

Net income (loss) per share Basic & Diluted

-0.05

-0.04

-0.05

-0.06

-0.09

-0.05

-0.06

Weighted average number of common shares outstanding Basic & Diluted

61,519

59

57

-53,191

53,301

51

49